TrialEuropean journal of cancer (Oxford, England : 1990)2016

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.

Kelly E Huibregtse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.